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Abstract 
Objective:  Probiotics and prebiotics that affect gut microflora balance and its associated 
enzyme activity may contribute to inter-individual variation in isoflavone absorption 
following soy intake, possibly enhancing isoflavone bioavailability.  This study examined 
the effects of the consumption of a probiotic (bioactive yogurt) or a prebiotic (resistant 
starch) in combination with high soy intake, on soy isoflavone bioavailability.   
Research Methods and Procedures: Using a crossover design, chronic soy consumption 
was compared with soy plus either probiotic or prebiotic foods in older male and 
postmenopausal females (n = 31).  Isoflavone bioavailability was assessed at the 
beginning and end of each 5 week dietary period by sampling plasma and urine after a 
standardized soy meal.  
Results: Chronic soy intake did not significantly affect plasma or urinary isoflavones 
following the soy meal and there were no significant effects of either probiotic or 
prebiotic treatment.  However, there were trends for increased circulating plasma 
daidzein and genistein after the probiotic treatment and for increased plasma daidzein and 
genistein 24 h post soy intake with the prebiotic treatment.  Neither probiotic nor 
prebiotic treatment induced or increased equol production, though there was a trend for 
increased plasma equol in “equol-positive” subjects (n = 12) after probiotic treatment.   
Conclusion: The weak or absence of effects of probiotic or prebiotic supplement to a 
chronic soy diet suggests that gut microflora were not modified in a manner that 
significantly affected isoflavone bioavailability or metabolism.  
Key Words: isoflavone, probiotic, prebiotic, bioavailability, daidzein, genistein
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INTRODUCTION 
Gut microflora plays an essential role in soy isoflavone absorption, metabolism and 
bioavailability by virtue of its enzymatic activity (1-3).  Differences in gut microfloral profiles 
may contribute to the large inter-individual variation typical for isoflavone bioavailability 
following soy intake.  The enzymes most pertinent to isoflavone bioavailability are the β-
glucosidases, for initial glucoside hydrolysis and subsequent aglycone absorption, and the β-
glucuronidases and sulphatases, for reabsorption of the hepatic conjugates and biliary excretion 
(4).  The initial hydrolysis of soy isoflavone glucosides to their respective aglycones is suggested 
to be the rate-limiting step in isoflavone absorption (5-7); thus, β-glucosidases activity may be 
particularly important in relation to isoflavone bioavailability.  Bacterial species of bacteroides, 
bifidobacteria and lactobacilli have the highest activity of this enzyme (7-9).   
Lactobacilli and bifidobacteria are unique in being exclusively beneficial to the host (10) 
and thus are termed “probiotic bacteria” (11).  Live cultures of these bacteria can be provided in 
food matrices, such as fermented milk products, to introduce them to the gastrointestinal tract 
(12) where they subsequently colonize the small intestine and colon (13).  Alternatively, the 
growth and/or activity of specific probiotic bacteria already resident in the gut can be selectively 
stimulated by intake of prebiotic dietary components (14).  Resistant starch is such a prebiotic; it 
is fermented in the large bowel specifically by bifidobacteria (15) and consequently increases β-
glucosidase activity (16).  By altering gut microflora balance and increasing β-glucosidase 
activity, probiotic bacteria may also enhance isoflavone absorption.  Furthermore, the metabolism 
of daidzein to equol relies exclusively on intestinal bacteria (17) and this conversion may be 
particularly important as equol has significantly enhanced antioxidant activity compared with 
daidzein (18,19) and may increase potential health benefits (20).  Thus, we hypothesized that 
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intake of either probiotic cultures or a prebiotic dietary component may affect soy isoflavone 
bioavailability, including equol production. A crossover study was conducted in which plasma 
and urinary isoflavone levels after 5 weeks of daily intake of soy foods were compared with those 
after 5 weeks of daily intake of soy in combination with either yogurt containing probiotic 
bacteria or bread containing the prebiotic, resistant starch. 
 
MATERIALS AND METHODS 
Subjects 
Male and female subjects, recruited via the local media, were required to be at least 45 
years old and mildly hypercholesterolemic (total cholesterol greater than 5.5 mmol/L).  A 
secondary aim of this study was to determine the effects of soy in combination with a probiotic or 
prebiotic on lipids (Larkin et al, manuscript submitted), hence the latter criterion.  Further, 
women had to be post-menopausal for more than 12 months and not taking hormone replacement 
therapy (HRT) for the previous 6 months.  Further exclusion criteria included the use of 
cholesterol-lowering medication, antibiotics or probiotic-containing foods or supplements within 
2 months prior to the study, an average alcohol intake of greater than 2 standard drinks per day 
and cigarette smoking.   
Study Design 
The study consisted of 2 separate cohorts, both of randomized crossover design (Figure 
1), with each subject acting as his or her own control.  The probiotic cohort was double-blinded; 
the prebiotic cohort was not blinded.  After a two-week wash-in period during which soy foods, 
yogurt, Hi-MaizeTM bread (high resistant starch content) and probiotic supplements were 
excluded from the diet, subjects commenced the study, which involved two 5-week dietary 
periods separated by a 4-week washout, which required the same dietary exclusions as the wash-
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in period.  Subjects were instructed to otherwise maintain their normal diets for the duration of 
the study so that other prebiotic dietary components would remain constant.  This study design 
enabled us to examine the effects of increased intake of probiotic yogurt or the prebiotic, resistant 
starch.  Subjects completed a dietary questionnaire during each of the wash-in and washout 
periods and during both dietary periods. 
All subjects consumed soy milk and soy cereal daily during both dietary periods; this diet 
was further supplemented with either the probiotic or prebiotic foods for the corresponding 
intervention.  A test soy meal was consumed prior to and at the end of both 5-week dietary 
periods for determination of subsequent isoflavone bioavailability.  Subjects were allocated to 
one of four groups (Pro-1, Pro-2, Pre-1 or Pre-2), which determined the intervention (probiotic or 
prebiotic) and the order of crossover (Figure 1).  The control and active dietary treatments for the 
probiotic cohort were soy + control yogurt (S + YC) and soy + probiotic yogurt (S + YP), 
respectively and for the prebiotic cohort were soy control (SC) and soy + resistant starch bread (S 
+ RS), respectively.  To assist with compliance, subjects with a preference for either yogurt or 
bread were allocated accordingly; otherwise, allocation to the probiotic or prebiotic intervention 
was random as was the order of the crossover.   
For each test meal and daily during both 5-week dietary periods, all subjects consumed 
250 mL soy milk (So Natural, UHT Calciforte, Taren Point, NSW, Australia) and 45 g soy cereal 
(Specialty Cereals, Mt Kuring-gai, NSW, Australia).  This provided a total of 38 mg daidzein and 
68 mg genistein and 4.5 mg glycitein, with the majority of this provided by the cereal (29 mg 
daidzein + 55 mg genistein + 4.5 mg glycitein).  Sufficient quantities of each food were provided 
to subjects at the beginning of each dietary period; soy milk was provided in 1 L cartons, from 
which subjects were asked to measure and consume 250 mL daily and soy cereal was pre-
packaged as individual 45 g serves.   
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For the probiotic intervention, subjects consumed 100 mL yogurt per day (Vaalia, Pauls 
Dairy, Brisbane, Qld, Australia) either with (probiotic) or without (control) live bacterial cultures.  
The probiotic yogurt contained 108 colony forming units (CFU)/100 g daily serve of each of 
Lactobacillus GG, Lactobacillus acidophilus and Bifidobacterium bifidus.  Both control and 
probiotic yogurts were vanilla flavored with “low” fat (1.4%) content; there were no flavor or 
texture differences between the two types and the containers were unmarked except for a 
numerical code.  Individual 100 mL serves of yogurt were provided fresh to subjects every 3 
weeks and stored under refrigeration.  For the prebiotic intervention, bread was baked using 70 % 
resistant starch flour (Penford Australia Ltd, Sydney, NSW, Australia) by a local bakery (K & M 
Bakery, Woonona, NSW, Australia) to provide approximately 4 g resistant starch per slice.  
Bread was baked every 2 - 3 weeks and either delivered to subjects on the day of baking or frozen 
in the clinic area for pick-up.  Subjects consumed 4 - 5 slices of bread per day (to provide a total 
of 16 - 20 g RS).   
At the start of weeks 0, 5, 9 and 14, subjects attended the clinic at the University of 
Wollongong on two consecutive days.  On the first morning, a fasted blood sample was taken, a 
food frequency questionnaire was administered, and subjects commenced a 24 h urine collection.  
Next, a test meal consisting of 250 mL soy milk and 45 g soy cereal was eaten as breakfast in the 
clinic.  Subjects were instructed not to consume any other soy foods, probiotics or prebiotics for 
48 h post-meal. Blood was again collected 8 and 24 h after the test meal and a second 24 h urine 
sample was collected between 24 and 48 h post-meal.  Urine was collected in 2.5 L bottles 
containing 1 g ascorbic acid; total volume of each 24 h collection was recorded and aliquots were 
stored at -80oC until analysis.  Blood was collected by a registered nurse in the clinic area into 
EDTA tubes (Sarstedt) which were inverted and placed on ice until centrifuged at 4oC for 10 min 
at 2100 g; plasma was harvested and stored at -80oC until analysis.   
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Sample Analysis 
Extraction of isoflavones from plasma and urine was based on published methods using 
β-glucuronidase enzymatic extraction (21) with modifications to optimize the procedure for local 
use (22) and measurement via HPLC with ECD (22).  All reagents and standards were obtained 
from Sigma-Aldrich (Castle Hill, NSW, Australia) and solvents used for extractions, standard 
preparations and HPLC analysis were HPLC grade (Crown Scientific, Moorebank, NSW, 
Australia).  In these purified, extracted samples, isoflavones were separated on a reverse phase C-
18 column (SGE Wakosil II 18RS), identified by HPLC (Shimadzu auto-injector) with an 
isocratic mobile phase of 50 mM sodium acetate buffer pH 4.8 with acetic acid / methanol (45 / 
55) and quantified by electrochemical detection at +750 mV (VT-03, Antec Leyden, 
Zoeterwoude, The Netherlands).  Mixed standards of genistein (Sigma, G6649), daidzein (Sigma, 
D7802), equol (Sigma, 45405), O-desmethylangolensin (ODMA; Plantech, UK) at 4 different 
concentrations (between 0.2 µM and 2 µM for plasma and between 0.2 µM and 4 µM for urine) 
were included in each HPLC run at least in triplicate.  Limits of quantification for plasma and 
urine, respectively were 5 ng/mL and 1 µg/mL, for daidzein and genistein, 15 ng/mL and 2 
µg/mL, for equol and 60 ng/mL and 6 µg/mL, for ODMA (22).  Within-run coefficients of 
variation for peak area of standards (% standard deviation/mean) were less than 5% for daidzein 
and genistein, less than 10% for equol and less than 20% for ODMA.  Recoveries were greater 
than 70% and calculated values were not adjusted for recovery. 
Ethics 
Ethical approval for this study was granted by the University of Wollongong Human 
Research Ethics Committee (Ethics Number 02/248) and all procedures complied with National 
Health and Medical Research Council standards required in Australia.  Written, informed consent 
was obtained from all subjects prior to commencement of the study.   
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Statistics 
Initially, the normality of data sets was examined and outliers were identified (SPSS 11.0 
and 11.5, SPSS Inc. Chicago, Illinois).  ANOVA with repeated measures and Bonferroni post-
hoc analysis (SPSS 11.5, SPSS Inc. Chicago, Illinois) were used and reported with F values, df 
(hypothesis df, error df) and p values.  Student’s t-tests were 2-tailed (Microsoft Excel/SPSS 
11.5, SPSS Inc. Chicago, Illinois).  All values are reported as mean ± SEM.   
 
RESULTS 
Thirty-six subjects (15 females and 21 males) commenced the study, however 5 people 
withdrew for personal reasons; consequently, 31 subjects (12 female and 19 male Australians of 
Caucasian background) completed the study.  The median subject age was 57.5 years (range 49 – 
72 years) and subject age was not significantly different between the groups (F = 1.020, p = 
0.399, one-way ANOVA with between groups analysis).  Mean intake of daidzein and genistein 
for each test soy meal and for the daily soy intake during dietary periods was 0.48 ± 0.01 and 
0.84 ± 0.02 mg/kg body mass, respectively. 
At week 0, females had significantly higher concentrations of plasma daidzein than males, 
but there was no gender difference in plasma genistein (F = 8.386, p = 0.007 and F = 2.859, p = 
0.102, respectively; one-way ANOVA with repeated measures and between groups analysis).  
There were no differences between males and females for week 0 urinary excretion of either 
daidzein or genistein (F = 1.555, p = 0.223 and F <0.0001, p = 0.992 respectively, one-way 
ANOVA with repeated measures and between groups analysis).  There was no significant order 
effect for either dietary intervention and therefore, the two groups of each cohort were combined 
for all analyses.  In week 0 of each dietary period, plasma daidzein and genistein were still 
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significantly elevated 24 h after the test soy meal compared with 0 h, as expected.  The 0 h 
plasma concentrations of daidzein and genistein were significantly increased after all four soy 
dietary periods, independent of treatment.   
In the probiotic cohort, S + YP did not affect plasma daidzein or genistein concentrations 
significantly differently compared with S + YC (F1,15 = 0.416, p = 0.528 and F1,15 = 0.813, p = 
0.382, respectively, three-way ANOVA with repeated measures; Figure 2, Table 1); however, 
there was a greater increase in 0 h plasma daidzein concentration after probiotic treatment 
compared with control, though this was not significant (F1,15 = 1.897, p = 0.189, two-way 
ANOVA with repeated measures).  After probiotic treatment, the plasma concentrations of 
daidzein and genistein at 0 h of week 5 were higher than those at 24 h of week 0; this was 
significant for genistein and almost so for daidzein (p = 0.043 and p = 0.058, respectively, 
Student’s paired t-tests).  In the prebiotic cohort, there were also no significant differences 
between S + RS and SC for plasma concentrations of either daidzein or genistein (F1,15 = 0.416, p 
= 0.528 and F1,15 = 0.813, p = 0.382, respectively, three-way ANOVA with repeated measures; 
Figure 3, Table 2).   
When the active treatments for the probiotic and prebiotic cohorts (S + YP and S + RS, 
respectively) were compared, there were no significant differences between them for their effects 
on plasma isoflavones (F = 0.440, p = 0.513 for daidzein and F = 0.623, p = 0.437 for genistein, 
two-way ANOVA with repeated measures and between-groups analysis, Figure 4).   
None of the four 5-week dietary treatments significantly affected urinary daidzein or 
genistein concentrations and there were no significant differences between S + YC and S + YP 
(daidzein: F1,15 = 0.013, p = 0.909; genistein: F1,15 = 0.499, p = 0.491) nor SC and S + RS 
(daidzein: F1,13 = 0.537, p = 0.477; genistein: F1,13 = 3.287, p = 0.093, three way ANOVA with 
repeated measures, Table 3).   
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There was high inter-individual variability in the occurrence of equol and ODMA in 
plasma and urine and subjects were classified into one of three subgroups based on distinct 
differences between the pattern and frequency of occurrence of equol in their plasma or urine.  
These subgroups were approximate tertiles: equol-positive (eql(+)) included 12 subjects who 
consistently had equol in their plasma and/or urine, equol-occasional (eql(o)) included 10 
subjects who had plasma or urinary equol in a single plasma or urine sample and equol-negative 
(eql(-)) included 9 subjects who never had equol in their plasma or urine.  There were no 
significant differences between subjects in these subgroups for body mass, BMI or age at 
baseline, nor in week 0 plasma or urinary concentrations of daidzein or genistein.  None of the 
treatments significantly affected the plasma or urinary concentrations of equol in either the eql(+) 
or eql(o) subjects, nor did any of the treatments induce equol formation in eql(-) subjects.   
Throughout the study, mean plasma daidzein and genistein tended to be lowest in eql(-) 
subjects and highest in eql(+) subjects; however, variability was large and there were no 
significant differences between the three subgroups (F = 1.113, p = 0.343 for daidzein and F = 
2.228, p = 0.127 for genistein, two-way ANOVA with repeated measures and between groups 
analysis, Figure 5).  There were no significant differences or trends between the subgroups for 
urinary excretion of daidzein or genistein (F = 0.157, p = 0.856 and F = 0.315, p = 0.732 
respectively, two-way ANOVA with repeated measures and between groups analysis).   
DISCUSSION 
In the current study, neither the addition of probiotic bacteria nor a prebiotic ingredient to 
a soy diet significantly affected isoflavone absorption or metabolism.  This was in contrast to our 
hypothesis that intake probiotic and prebiotic intake, by virtue of their individual effects on gut 
microflora and enzyme activity necessary for isoflavone absorption and metabolism could 
potentially increase isoflavone bioavailability.   
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The lack of any significant effects of probiotic intake may indicate either that the levels of 
probiotic bacteria provided were insufficient to affect gut microfloral balance or that any gut 
microfloral changes that did occur did not further affect isoflavone absorption.  Our probiotic 
yogurt was purported by the supplier to contain 108 colony forming units (CFU)/100 g of each of 
Lactobacillus acidophilus, Bifidobacterium bifidus and Lactobacillus GG.  This level of bacterial 
activity should be sufficient to affect gut microfloral balance as probiotic effects in the 
gastrointestinal tract have been reported with minimum daily doses of between 108 and 109 viable 
cells (13,23-25).  Oral administration of these probiotic bacteria results in increased populations 
in the human gastrointestinal tract and faeces (25-28, 31-35) and increased fecal β-glucosidase 
activity (36).  Such increases in lactobacilli and bifidobacteria intake and concomitant 
enhancement in intestinal β-glucosidase activity would be expected to enhance initial hydrolysis 
and absorption of dietary isoflavone glycosides.  However, a recent randomized, crossover trial 
with 40 postmenopausal women also reported no effect of bacterial supplementation (109 CFU 
Lactobacillus acidophilus and Bifidobacterium longum) with daily intake of soy protein isolate 
plus 44 mg isoflavones on plasma isoflavone concentrations after 6 weeks (37).  Together with 
our study, this suggests that soy isoflavone bioavailability is not affected by concurrent probiotic 
intake as either a supplement (37) or a dietary component (current study).   
The absence of any significant changes in isoflavone bioavailability with resistant starch 
intake again suggests either a lack of effect on the gut microflora or that such effects had no 
impact on isoflavone absorption and metabolism.  Although we did not determine gastrointestinal 
microbial activity in the current study, prebiotic effects have been reported after 2 – 4 weeks of 
daily RS intake of between 15 and 55 g (38-42), thus it is likely the RS intake in the current study 
had a similar effect.  Resistant starch specifically stimulates the growth of bifidobacteria in the 
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colon (15,43) and increases caecal lactobacilli and bifidobacteria levels in human flora-associated 
rats (16).  Bifidobacteria can hydrolyze daidzin and genistin from soy milk to their respective 
aglycones (44) and metabolize daidzein in human faecal samples (45,46) and these effects have 
been attributed to its β-glucosidase activity (36,44).  Both bifidobacteria and lactobacilli possess 
high β-glucosidase activity (16,36) and are also the dominant native microflora in the duodenum 
and jejunum where most of the initial isoflavone hydrolysis is likely to occur (9).  Interestingly, 
Lactobacillus acidophilus and Bifidobacterium bifidus do not increase β-glucuronidase activity in 
the human gastrointestinal tract (29,36,47,48), thus the lack of prebiotic or probiotic observed 
here suggest that β-glucuronidase activity may be more important than β-glucosidase activity in 
isoflavone bioavailability.   
Although subjects were instructed to maintain their normal diets, many foods contain 
prebiotics and contribute to the microbial activity of the gastrointestinal tract.  With no measure 
of this in the current study, we are unable to attribute the results of resistant starch intake to a 
specific prebiotic effect.  Fructooligosaccharide (FOS), a prebiotic similar to RS, also increases 
fecal bifidobacteria (49) and affects gut microflora balance (50) and was reported to prolong the 
clearance of daidzein and genistein and increase their bioavailability in rats (51).  We previously 
found altered isoflavone metabolism with resistant starch intake, including enhanced metabolism 
of daidzein to equol (Larkin et al, manuscript submitted).  In the current study, the mean plasma 
isoflavone concentrations 24 h post-meal were highest after 5 weeks of soy and resistant starch 
intake and although not significant, this finding is interesting to note as it also suggests prolonged 
plasma isoflavone clearance following a single soy meal.  Overall, there may be a potential 
prebiotic effect on isoflavone bioavailability; however, the relevance of dietary-induced changes 
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in gastrointestinal microfloral activity to isoflavone bioavailability is rather poorly understood 
and requires further investigation. 
In the current study, 12 subjects (39%) consistently metabolized daidzein to equol, a 
similar proportion to that reported in other soy studies (52-54).  All four soy dietary periods 
increased plasma equol levels in the initial (0 h) measurement, implying that 5 weeks of daily soy 
intake (with or without a probiotic or prebiotic) was sufficient to increase plasma equol in those 
who are predisposed to this conversion.  However, the concurrent consumption of either a 
probiotic or prebiotic with soy did not affect equol concentration or the number of people who 
produced equol, nor did it induce equol production.  Lactobacilli and bifidobacteria have been 
identified as playing a role in the metabolism of daidzein to equol (17,44,55) (56) and the short 
chain fatty acid products of resistant starch intestinal fermentation (42,57,58) increase daidzein 
conversion to equol in faeces (17); however, increased intake of either these probiotic bacteria or 
resistant starch did not affect equol production in the current study.  Previous studies also report 
no effect of either probiotic (37) or dietary fibre (52) supplementation with soy consumption on 
equol-producing capacity, suggesting genetics may contribute to this ability (59).  In the current 
study, equol occurrence varied greatly between individuals and within subjects on different 
occasions, as has been previously reported (60-62).  This large variability, combined with a small 
numbers of subjects, was a clear limitation.  There was a pattern however, although not 
significant, for subjects who produced equol to have higher plasma concentrations of daidzein 
and genistein, suggesting that a high level of initial isoflavone absorption may be a determining 
factor for equol production, as previously proposed (44).  
CONCLUSIONS 
Concurrent consumption of soy with either a probiotic or prebiotic dietary component did 
not significantly alter plasma or urinary daidzein or genistein concentrations or equol-producing 
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ability of the subjects in this study.  However, our results suggest minor effects on soy isoflavone 
bioavailability with probiotic or prebiotic intake.  Further investigation, including exploration 
into the roles of specific gut microflora, will assist in the establishment of dietary conditions to 
enhance isoflavone bioavailability and equol production, particularly if the latter is conclusively 
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FIGURE LEGENDS  
 
Figure 1. Study Design.  There were 2 groups for each cohort: probiotic (Pro-1 and Pro-2) and 
prebiotic (Pre-1 and Pre-2); these followed complementary orders of dietary treatments. S+YC = 
soy plus control yogurt; S+YP = soy plus probiotic yogurt; SC = soy control, S+RS = soy plus 
resistant starch.  Soy test meals were given at the beginning and end of each 5 week dietary 
period.  
 
Figure 2. Probiotic cohort - Effect of 5 weeks soy + control yogurt (S + YC) and 5 weeks soy + 
probiotic yogurt (S + YP) on mean plasma daidzein and genistein concentrations.  Mean ± SEM, 
n = 17.  *Significant p<0.017, post-hoc Student’s paired t-tests with Bonferroni adjustment. 
 
Figure 3. Prebiotic cohort - Effect of 5 weeks soy control (SC) and 5 weeks soy + resistant starch 
(S + RS) on mean plasma daidzein and genistein concentrations.  Mean ± SEM, n = 14.  
*Significant p<0.017, post-hoc Student’s paired t-tests with Bonferroni adjustment. 
 
Figure 4. Change in plasma daidzein and genistein after 5 weeks of soy + probiotic yogurt (S + 
YP) and 5 weeks of soy + resistant starch (S + RS). 
 
Figure 5. Mean plasma daidzein and genistein concentrations throughout the study based on 
equol-producing ability of subjects as determined by HPLC quantification of samples: eql (+) 
subjects consistently had plasma and/or urinary equol, n = 12; eql (o) subjects had equol in a 
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single plasma or urine sample, n = 10; eql (-) subjects had no observable plasma or urinary equol, 
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 Plasma sample * time† week‡ week x time‡
 
 
Week 0 h 8 h 24 h F 2,14 p F 1,15 p F 2,14 p 
daidzein 0 
1.9 ± 1.5 a
(0 – 23.6) 
169 ± 19.3 b
(65.3 – 333) 
38.3 ± 8.5 c
(0 – 156) 
36.615 <0.0001 
(ng/mL) 
S + YC 
5 
45.0 ± 16.8 a
(0 – 260) 
193 ± 22.7 b
(50.4 – 350) 
41.2 ± 12.0 a
(4.1 – 190) 
35.195 <0.0001 
9.905 0.007 5.393 0.018 
 0 
3.0 ± 2.2 a
(0 – 34.2) 
176 ± 20.4 b
(33.0 – 374) 
30.3 ± 5.7 c
(0 – 78.5) 
33.805 <0.0001 
 
S + YP 
5 
66.2 ± 17.8 d
(4.1 – 237) 
154 ± 20.8 e
(12.2 – 364) 
34.5 ± 5.9 d
(0 – 97.0) 
17.035 <0.0001 
5.636 0.031 5.646 0.016 
genistein 0 
3.5 ± 2.4 a
(0 – 31.9) 
412 ± 53.5 b
(129 – 1009) 
134 ± 18.0 c
(23.0 – 281) 
34.022  <0.0001 
(ng/mL) 
S + YC 
5 
158 ± 38.8 a
(0 – 514) 
472 ± 57.8 b
(149 – 1019) 
175 ± 34.4 a
(32.5 – 487) 
23.725 <0.0001 
8.205 0.012 5.641 0.061 
 0 
2.8 ± 1.7 a
(0 – 20.3) 
412 ± 64.7 b
(67.2 – 972) 
116 ± 17.8 c
(14.8 – 295) 
21.271 <0.0001 
 
S + YP 
5 
201 ± 45.5 d
(46.1 – 682) 
401 ± 49.4 e
(38.8 – 701) 
144 ± 24.9 d
(42.4 – 454) 
16.387 <0.0001 
13.810 0.002 8.199 0.004 
* Values in a row with different superscript letters are significantly different. a, b, c - p < 0.002, d – p < 0.05, Bonferroni post-hoc analysis. 
†One-way ANOVA with repeated measures.   
















 Plasma sample * time† week‡ week x time‡
 
 
Week 0 h 8 h 24 h F 2,11 p F 1,12 p F 2,11 p 
daidzein 0 
2.2 ± 1.2 a
(0 – 13.1) 
158 ± 20.4 b
(72.9 – 303) 
36.0 ± 7.6 c





43.1 ± 12.9 a
(0 – 162) 
187 ± 21.7 b
(57.1 – 346) 
38.7 ± 7.9 a
(6.1 – 104) 
47.316 <0.0001 
18.710 0.001 5.401 0.023 
 0 
4.9 ± 3.9 a 
(0 – 54.7) 
170 ± 19.0 b
(68.3 – 324) 
37.5 ± 8.1 c
(8.4 – 93.4) 
39.946 <0.0001 
 
S + RS 
5 
45.7 ± 10.4 a
(0 – 133) 
182 ± 21.1 b
(66.0 – 357) 
56.3 ± 15.1 a
(12.3 – 198) 
44.655 <0.0001 
5.355 0.039 4.569 0.036 
genistein 0 
1.7 ± 1.2 a
(0 – 14.7) 
388 ± 49.2 b
(167 – 744) 
113 ± 10.6 c





197 ± 47.4 a
(58.3 – 598) 
479 ± 51.6 b
(139 – 800) 
167 ± 24.0 a
(66.6 – 365) 
51.883 <0.0001 
45.825 0.000 4.900 0.030 
 0 
2.2 ± 1.7 a
(0 – 24.1) 
403 ± 56.3 b
(129 – 938) 
143 ± 33.7 c
(44.6 – 486) 
52.852 <0.0001 
 
S + RS 
5 
153 ± 27.7 a
(0 – 355) 
516 ± 69.1 b
(140 – 1010) 
215 ± 60.2 a
(67.5 – 876) 
30.018 <0.0001 
14.044 0.003 4.484 0.038 
* Values in a row with different superscript letters are significantly different. p < 0.02, Bonferroni post-hoc analysis. 
†One-way ANOVA with repeated measures. 











Table 3. Urinary daidzein and genistein concentrations – A. probiotic cohort; B. prebiotic cohort. 
 
   Wk 0 – 24 h* 24 - 48 h 0 – 48 h F1,15† p p‡
A. 
daidzein 0 
12.0 ± 1.0 
(5.8 – 21.7) 
5.0 ± 1.4 
(0.79 – 21.6) 
17.0 ± 1.9 
(10.1 – 37.6) 0.001 
 (mg) 
S + YC 
5 
13.2 ± 1.3 
(3.2 – 20.4) 
4.6 ± 1.4 
(0.47 – 23.1) 
17.8 ± 2.1 





12.0 ± 1.3 
(3.8 – 20.1) 
4.1 ± 1.1 
(0.68 – 16.8) 
16.1 ± 2.0 
(5.8 – 30.4) <0.0001 
 
 
S + YP 
5 
14.2 ± 1.6 
(4.0 – 27.8) 
4.8 ± 0.91 
(1.6 – 15.5) 
19.0 ± 2.1 





6.1 ± 0.68 
(2.1 – 11.8) 
2.4 ± 0.80 
(0 – 11.8) 
8.5 ± 1.1 
(2.5 – 16.0) 0.003 
 (mg) 
S + YC 
5 
7.6 ± 1.0 
(1.5 – 17.1) 
3.1 ± 1.5 
(0 – 25.3) 
10.8 ± 2.2 





5.8 ± 0.79 
(1.3 – 10.9) 
2.0 ± 0.91 
(0 – 15.1) 
7.7 ± 1.3 
(1.6 – 20.6) 0.005 
 
 
S + YP 
5 
7.4 ± 0.97 
(0.81 – 16.9) 
2.5 ± 0.62 
(0 – 7.4) 
9.9 ± 1.5 





10.4 ± 2.4 
(2.8 – 18.3) 
2.4 ± 0.45 
(0.57 – 18.3) 
12.7 ± 1.2 




13.5 ± 2.3 
(0 – 34.8) 
4.9 ± 1.6 
(0.69 – 23.0) 
18.1 ± 3.2 





10.3 ± 1.4 
(3.3 – 21.3) 
4.2 ± 1.1 
(0.80 – 13.9) 
14.2 ± 2.2 
(4.3 – 28.9) <0.0001 
 
 
S + RS 
5 
12.4 ± 2.1 
(4.2 – 39.0) 
6.5 ± 2.1 
(1.2 – 25.7) 
18.5 ± 3.6 





5.7 ± 0.87 
(1.4 – 13.6) 
0.81 ± 0.14 
(0.20 – 2.2) 
6.4 ± 0.97 




7.2 ± 1.3 
(0 – 16.7) 
1.8 ± 0.52 
(0 – 6.2) 
8.8 ± 1.6 





6.7 ± 1.4 
(1.5 – 17.4) 
2.6 ± 0.82 
(0 – 9.1) 
9.1 ± 2.0 
(1.5 – 25.2) 0.001 
 
 
S + RS 
5 
7.0 ± 0.84 
(2.3 – 13.4) 
2.8 ± 0.86 
(0.30 – 10.5) 
9.7 ± 1.5 
(2.6 – 21.9) 
0.036 0.853 
<0.0001 
*Mean ± SEM (range in parentheses) 
†Two way ANOVA with repeated measures for effect of dietary period on 0 – 24 h and 24 – 48 h urinary isoflavone excretion. 
Table 4. Plasma and urinary equol concentrations for equol-positive subjects (n = 12). 
 
   Plasma equol (ng/mL) Urinary equol (mg) 
Cohort Treatment Wk 0 h 8 h 24 h 0 – 24 h 24 – 48 h
Probiotic 0 0 37.5 ± 25.5 46.1 ± 26.9 2.4 ± 2.4 1.1 ± 1.0 
 
S + YC 
5 49.7 ± 17.7 53.8 ± 32.6 31.7 ± 18.8 1.2 ± 1.1 1.3 ± 1.0 
 0 26.4 ± 19.6 49.3 ± 30.4 39.7 ± 13.5 1.1 ± 0.47 0.51 ± 0.40 
 S + YP 5 69.9 ± 45.0 60.1 ± 34.8 64.0 ± 31.2 1.9 ± 1.5 2.0 ± 1.2 
Prebiotic 0 11.2 ± 11.2 43.6 ± 20.8 31.1 ± 13.3 0.83 ± 0.71 0.28 ± 0.15 
 SC 5 37.2 ± 10.5 30.4 ± 16.8 46.9 ± 11.8 1.2 ± 0.68 0.35 ± 0.14 
 0 6.7 ± 4.5 29.5 ± 17.0 29.8 ± 21.5 0.44 ± 0.43 0.80 ± 0.65 
 S + RS 5 28.2 ± 16.2 44.0 ± 18.6 29.6 ± 10.6 0.85 ± 0.85 0.95 ± 0.54 
 
